Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

August 12, 2019August 12, 2019

Sarcopenia May Affect up to 55% of Patients with SSc, Study Suggests

News

Loss of muscle mass and strength — known as sarcopenia — may affect up to 55% of patients with systemic sclerosis (SSc), a study suggests. Moreover, sarcopenia was found ... Read more

August 9, 2019August 9, 2019

High Levels of IL-6 Correlate with More Severe Skin Disease in SSc, Study Shows

News

Levels of a pro-inflammatory signaling molecule, called interleukin (IL)-6, are significantly high in skin lesions and blood samples of patients with systemic sclerosis (SSc), especially among those with diffuse ... Read more

August 5, 2019August 5, 2019

ACE Inhibitors Raise Risk of Renal Crisis in Some SSc Patients, Study Says

News

Systemic sclerosis (SSc) patients with elevated protein in their urine (proteinuria) who are using angiotensin-converting enzyme (ACE) inhibitors (ACEi) are at higher risk of developing scleroderma renal crisis (SRC), ... Read more

July 17, 2019July 17, 2019

Rituximab’s Immunosuppressive Effects Go Beyond B Cells in SSc, Study Finds

News

Rituximab, an immunosuppressant antibody designed to target immune B cells, has widespread effects and decreases subtypes of other immune cells called T cells in the skin and blood of ... Read more

July 3, 2019July 3, 2019

Levels of Two Blood Proteins Predict Course of ILD in SSc, Data Suggest

News

High levels of two proteins in the blood, called KL-6 and CCL-18, may work as biomarkers for predicting disease severity and progression of interstitial lung disease (ILD) in systemic sclerosis ... Read more

June 26, 2019June 26, 2019

Anti-cancer Therapy May Help Fight Inflammation in SSc Patients, Data Suggest

News

Tagraxofusp, a medicine approved in the U.S. under the name Elzonris to treat a rare blood cancer, may help decrease levels of immune cells that promote inflammation in systemic ... Read more

June 14, 2019June 14, 2019

Lenabasum Promotes Sustained Improvements in Systemic Sclerosis Patients, Extension Study Shows

News

People with diffuse cutaneous systemic sclerosis (dcSSc) treated with lenabasum keep improving after 21 months of treatment, results from a Phase 2 open-label extension study show. Robert Spiera, MD, from ... Read more

June 7, 2019June 7, 2019

Blocking Specific ‘Signaling Molecule’ Seen to Ease Inflammation, Scarring in Early Study

News

Targeting a signaling molecule called CCL24 with a new antibody was seen to lessen inflammation and scarring (fibrosis) in a mouse model of systemic sclerosis (SSc), research shows. The ... Read more

May 3, 2019May 3, 2019

PF Combined with Emphysema Decreases Survival Rates of Systemic Sclerosis Patients, Data Analysis Shows

News

Combined pulmonary fibrosis and emphysema (CPFE) impairs lung function and decreases survival rates of systemic sclerosis (SSc) patients, a retrospective analysis shows. The study “Overall mortality in combined pulmonary ... Read more

April 12, 2019April 12, 2019

Estradiol Could Be Key Therapeutic Target Against dcSSc, Study Suggests

News

Men older than 50 with diffuse cutaneous systemic sclerosis (dcSSc) have higher levels of estradiol, an active form of estrogen, in their blood compared to healthy males, a study ... Read more

Pin It on Pinterest